In a report released today, from Jefferies maintained a Buy rating on Incyte, with a price target of $120.00. In addition to Jefferies, Incyte also......

Guggenheim analyst Michael Schmidt maintained a Buy rating on Incyte yesterday and set a price target of $130.00. According to TipRanks, Schmidt is......

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Incyte today and set a price target of $102.00. Frommer covers the Healthcare sect......

Incyte (($INCY)) has held its Q4 earnings call. Read on for the main highlights of the call. Incyte’s latest earnings call struck an optimistic ton......

Incyte ($INCY) announced an update on their ongoing clinical study. Tafasitamab-Parsaclisib Basket Trial Halted A Phase 1b/2a basket trial titled “......

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD – Research Report), Roche Holding AG (......

Analysts fell to the sidelines weighing in on Outset Medical (OM – Research Report) and Incyte (INCY – Research Report) with neutral ratings, indic......

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte’s latest clinical update centers on a Phase 0 observational study titled......

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report), SI-Bone (SIBN – R......